Pan et al. (2015), reported that p53 hybrid phage‐based ELISA for detection of anti‐p53 antibody in patients with a malignant tumour had a lower detection rate than ELISA with recombinant protein, but using both recombinant protein and hybrid phage increased the detection rate (Pan et al., 2015). The gene discussed is TP53; the disease is cancer.